Shire Vs Allergan Brings Exclusive Contracts Out Of The Shadows (Again)
Executive Summary
Allergan's Medicare Part D contracting tactics for Restasis have blocked Xiidra from the market, Shire lawsuit claims.
You may also be interested in...
Shire Touts Ongoing Xiidra Growth, Targets Increased Medicare Access
Company outlines manufacturing streamlining and efficiency effort that it expects to add significant cost savings above synergies anticipated from merger with Baxalta.
Allergan Shifts Restasis Patents To Native American Tribe To Invoke Immunity From IPR
The tribe will move to get IPR proceedings dismissed, but the strategy isn't expected to affect ANDA litigation. Allergan's CEO said the company could use a similar approach with other patents and notes that other companies may follow.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.